Search
venetoclax (Venclexta)
Indications:
- treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion
Dosage:
- week 1: 20 mg PO QD
- week 2: 50 mg PO QD
- week 3: 100 mg PO QD
- week 4: 200 mg PO QD
- week 5: 400 mg PO QD (recommended daily dose of 400 mg)
PO QD with food & water
do not chew, crush, or break tablets [4]
Tablets: 10 mg, 50 mg, 100 mg. [5]
Adverse effects:
- Serious adverse reactions were reported in 44% of patients
- pneumonia
- febrile neutropenia, pyrexia
- autoimmune hemolytic anemia
- tumor lysis syndrome
- aggressive hydration plus allopurinol or rasburisase to to prevent tumor lysis syndrome [4]
- diarrhea, nausea
- upper respiratory tract infection
- thrombocytopenia
- fatigue
- fetal injury in pregnant women
Drug interactions:
- CYP3A inhibitors
- do not use during induction phase
- for maintenance phase, reduce dose of venetoclax by at least 75% when used concomitantly with strong CYP3A inhibitors
- avoid grapefruit
- avoid coadministration with narrow therapeutic window P-glycoprotein substrates (digoxin, everolimus, sirolimus)
- monitor INR closely in patients taking warfarin
- live attenuated vaccine contraindicated
Mechanism of action:
- BCL-2 selective inhibitor
General
antineoplastic agent (chemotherapeutic agent)
Database Correlations
PUBCHEM correlations
References
- Venclexta
https://www.venclexta.com/hcp.html
- FDA News Release. April 11, 2016
FDA approves new drug for chronic lymphocytic leukemia in
patients with a specific chromosomal abnormality.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm495253.htm
- Windle ML
FDA Drug Approvals and Changes: May edition.
Medscape. May 20, 2016
http://reference.medscape.com/features/slideshow/drug-review/2016/may
- VENCLEXTA PRESCRIBING INFORMATION
http://www.rxabbvie.com/pdf/venclexta.pdf
- Medscape: venetoclax (Rx)
https://reference.medscape.com/drug/venclexta-venetoclax-1000078